Anifrolumab showed benefit across different measures of skin and joint disease activity in patients with systemic lupus erythematosus
A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE).[1] The analysis examined disease manifestations in the two most commonly impacted organ domains in SLE.[2-3] Anifrolumab is a potential first-in-class type I interferon inhibitor. For skin rash, the